A phase I/Ib, randomized, double-blind, placebo-controlled, dose escalation study to evaluate the safety, tolerability and pharmacokinetics of a single dose of Nemolizumab (CIM331) in healthy Japanese and Caucasian volunteers and Japanese patients with atopic dermatitis.

Trial Profile

A phase I/Ib, randomized, double-blind, placebo-controlled, dose escalation study to evaluate the safety, tolerability and pharmacokinetics of a single dose of Nemolizumab (CIM331) in healthy Japanese and Caucasian volunteers and Japanese patients with atopic dermatitis.

Completed
Phase of Trial: Phase I

Latest Information Update: 13 Jul 2017

At a glance

  • Drugs Nemolizumab (Primary)
  • Indications Atopic dermatitis
  • Focus Adverse reactions; Pharmacokinetics
  • Sponsors Chugai Pharmaceutical
  • Most Recent Events

    • 13 Jul 2017 Results of population pharmacokinetic analysis from two studies including this study published in the Journal of Clinical Pharmacology
    • 26 Sep 2015 Results published in the British Journal of Dermatology.
    • 26 Sep 2015 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top